Daniel R Morales
Overview
Explore the profile of Daniel R Morales including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Downes T, Guthrie B, Moreno-Martos D, Morales D
Heart
. 2025 Mar;
PMID: 40037761
Background: Atrial fibrillation (AF) prevalence is rising due to population ageing and comorbidity is an increasing problem. The aim of this study was to examine the prevalence and association of...
2.
Janetzki J, Kim J, Minty E, Lee J, Morales D, Khera R, et al.
EClinicalMedicine
. 2025 Feb;
81:103096.
PMID: 39975698
Background: Fluoroquinolones (FQs) are commonly used to treat urinary tract infections (UTIs), but some studies have suggested they may increase the risk of aortic aneurysm or dissection (AA/AD). However, no...
3.
Abellan A, Burn E, Trinh N, Burkard T, Callahan A, Fernandez-Bertolin S, et al.
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(2):e70106.
PMID: 39950235
Objectives: The Observational Medical Outcomes Partnership common data model (OMOP-CDM) is a useful tool for large-scale network analysis but currently lacks a structured approach to pregnancy episodes. We aimed to...
4.
Fleetwood K, Guthrie B, Jackson C, Kelly P, Mercer S, Morales D, et al.
PLoS Med
. 2025 Feb;
22(2):e1004532.
PMID: 39946376
Background: Depression is associated with a range of adverse physical health outcomes. We aimed to quantify the association between depression and the subsequent rate of accrual of long-term physical health...
5.
Mumtaz S, McMinn M, Cole C, Gao C, Hall C, Guignard-Duff M, et al.
J Med Internet Res
. 2025 Jan;
27:e52385.
PMID: 39819848
Background: Clinical guideline development preferentially relies on evidence from randomized controlled trials (RCTs). RCTs are gold-standard methods to evaluate the efficacy of treatments with the highest internal validity but limited...
6.
Gao C, Mumtaz S, McCall S, OSullivan K, McGilchrist M, Morales D, et al.
J Biomed Inform
. 2025 Jan;
162:104771.
PMID: 39755323
Objective: Medical laboratory data together with prescribing and hospitalisation records are three of the most used electronic health records (EHRs) for data-driven health research. In Scotland, hospitalisation, prescribing and the...
7.
Karres D, Pino-Barrio M, Benchetrit S, Benda N, Cochat P, Galluzzo S, et al.
Br J Pharmacol
. 2024 Nov;
182(3):484-494.
PMID: 39574299
Drug development for children presents unique challenges and is highly regulated. Novel approaches, such as the use of extrapolation to address, for example, the need to avoid unethical studies, whilst...
8.
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, et al.
J Am Coll Cardiol
. 2024 Aug;
84(10):904-917.
PMID: 39197980
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)....
9.
Du M, Dernie F, Catala M, Delmestri A, Man W, Brash J, et al.
Eur J Intern Med
. 2024 Aug;
130:106-117.
PMID: 39134452
Objective: Multiple treatment options are recommended for Systemic Lupus Erythematosus (SLE) by clinical guidelines. This study aimed to explore SLE treatment patterns as there is limited real-world data of SLE...
10.
Goedecke T, Martirosyan L, Gault N, Seifert K, Morales D, Bahri P, et al.
Pharmacoepidemiol Drug Saf
. 2024 Aug;
33(8):e5874.
PMID: 39092454
Purpose: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) launched a strategy to examine the public health impact of major regulatory interventions aimed at minimising risks of medicinal...